Harbin Pharmaceutical Group Co Ltd banner

Harbin Pharmaceutical Group Co Ltd
SSE:600664

Watchlist Manager
Harbin Pharmaceutical Group Co Ltd Logo
Harbin Pharmaceutical Group Co Ltd
SSE:600664
Watchlist
Price: 3.88 CNY -1.27% Market Closed
Market Cap: ¥9.8B

EV/EBIT

11.8
Current
10%
More Expensive
vs 3-y average of 10.7

Enterprise Value to EBIT (EV/EBIT) ratio compares a company`s total enterprise value to its earnings before interest and taxes. It shows how much investors are paying for each dollar of the company`s earnings, including both equity and debt.

EV/EBIT
11.8
=
Enterprise Value
¥8.9B
/
EBIT
¥689.4m

Enterprise Value to EBIT (EV/EBIT) ratio compares a company`s total enterprise value to its earnings before interest and taxes. It shows how much investors are paying for each dollar of the company`s earnings, including both equity and debt.

EV/EBIT
11.8
=
Enterprise Value
¥8.9B
/
EBIT
¥689.4m

Valuation Scenarios

Harbin Pharmaceutical Group Co Ltd is trading above its 3-year average

If EV/EBIT returns to its 3-Year Average (10.7), the stock would be worth ¥3.51 (9% downside from current price).

Statistics
Positive Scenarios
2/4
Maximum Downside
-9%
Maximum Upside
+145%
Average Upside
56%
Scenario EV/EBIT Value Implied Price Upside/Downside
Current Multiple 11.8 ¥3.88
0%
3-Year Average 10.7 ¥3.51
-9%
5-Year Average 10.8 ¥3.54
-9%
Industry Average 23.4 ¥7.71
+99%
Country Average 28.9 ¥9.5
+145%

Forward EV/EBIT
Today’s price vs future ebit

Today's Enterprise Value EBIT Forward EV/EBIT
¥8.9B
/
Oct 2025
¥689.4m
=
11.8
Current
¥8.9B
/
Dec 2025
¥1.1B
=
8.3
Forward
¥8.9B
/
Dec 2026
¥1.3B
=
7
Forward
¥8.9B
/
Dec 2027
¥1.5B
=
5.9
Forward

Forward EV/EBIT shows whether today’s EV/EBIT still looks high or low once future ebit are taken into account.

Peer Comparison

All Multiples
EV/EBIT
P/E
All Countries
Close
Market Cap EV/EBIT P/E
CN
Harbin Pharmaceutical Group Co Ltd
SSE:600664
9.8B CNY 11.8 21.8
US
Eli Lilly and Co
NYSE:LLY
835.2B USD 29.2 40.5
US
Johnson & Johnson
NYSE:JNJ
547.8B USD 21.4 26
CH
Roche Holding AG
SIX:ROG
248.4B CHF 13.4 20.1
UK
AstraZeneca PLC
LSE:AZN
216.4B GBP 21.9 28
CH
Novartis AG
SIX:NOVN
223.1B CHF 15.6 19.5
US
Merck & Co Inc
NYSE:MRK
276.9B USD 11.5 15.2
IE
Endo International PLC
LSE:0Y5F
244.4B USD 970 -83.6
DK
Novo Nordisk A/S
CSE:NOVO B
1.1T DKK 9.8 11.4
US
Pfizer Inc
NYSE:PFE
153.5B USD 10.1 19.8
US
Bristol-Myers Squibb Co
NYSE:BMY
118.2B USD 8.9 16.8

Market Distribution

Lower than 81% of companies in China
Percentile
19th
Based on 5 337 companies
19th percentile
11.8
Low
0 — 16.6
Typical Range
16.6 — 52.9
High
52.9 —
Distribution Statistics
China
Min 0
30th Percentile 16.6
Median 28.9
70th Percentile 52.9
Max 49 021

Harbin Pharmaceutical Group Co Ltd
Glance View

Market Cap
9.8B CNY
Industry
Pharmaceuticals

Founded amidst the industrial boom of the 1950s, Harbin Pharmaceutical Group Co., Ltd. has evolved into one of China's pharmaceutical giants, headquartered in Harbin, Heilongjiang Province. Historically grounded in traditional Chinese medicine, it has grown into a multifaceted enterprise that blends its cultural heritage with modern pharmaceutical science. Harbin Pharma's journey from its humble beginnings to becoming a household name is marked by its robust research and development efforts, which are key to its operations. The company's vertical integration strategy stretches through the entire pharmaceutical value chain, encompassing research, production, and distribution, thereby optimizing efficiency and maintaining quality control across its vast product lines. This structure not only helps minimize costs but also allows Harbin Pharma to quickly adapt to changes in the healthcare market. The company primarily generates revenue through the production and sale of both prescription and over-the-counter drugs, catering to a diverse array of health needs globally. A significant portion of its income stems from the manufacture of antibiotics, patent drugs, and biological products, though it also maintains a strong presence in the consumer health sector with vitamins and dietary supplements. Strategically, Harbin Pharma leverages its extensive distribution network, one of the largest in China, ensuring that its products reach even the most remote areas. Moreover, the company benefits from partnerships and collaborations with international pharmaceutical companies, which allow it to expand its global footprint and enhance its product offerings. In essence, Harbin Pharmaceutical Group's success is anchored in its adaptive business strategies, commitment to innovation, and ability to navigate the complexities of the rapidly evolving pharmaceutical landscape.

Intrinsic Value
5.94 CNY
Undervaluation 35%
Intrinsic Value
Price ¥3.88
Get AI-powered insights for any company or topic.
Open AI Assistant

Intrinsic Value is all-important and is the only logical way to evaluate the relative attractiveness of investments and businesses.

Warren Buffett